Omalizumab Shows Continued Efficacy for Chronic Rhinosinusitis With Nasal Polyps
Treatment with omalizumab for up to 1 year was associated with continued improvements in symptoms of chronic rhinosinusitis with nasal polyps.
ACAAI 2020
Complete Coverage
Exhalation Delivery System vs Intranasal Spray for Nasal Polyp Treatment
An exhalation delivery system appears to more effectively apply topical steroids to nasal polyps located in the ostiomeatal complex.
Potential Sex Differences in Chronic Cough Triggers
Women with chronic cough in the United States and United Kingdom were more likely to have a higher number of cough triggers.
Asthma Prevalence May Be Higher in Elderly With Behavioral Health Issues
Because of the prevalence of behavioral health issues in elderly patients with asthma, appropriate behavioral health treatment may improve patient outcomes.
Crisaborole Safe, Efficacious in Atopic Dermatitis, With or Without Allergic Rhinitis
The safety and efficacy of crisaborole ointment, 2%, was examined in pediatric patients with mild to moderate atopic dermatitis with and without comorbid allergic rhinitis.
Atopic Dermatitis Does Not Appear to Affect COVID-19 Severity
Investigators evaluated the relationship between atopic dermatitis and frequency of severity markers in patients hospitalized with COVID-19.
Pulse Oximetry, Vital Signs May Predict Hospital LOS in Pediatric Asthma Exacerbations
Heart rate, respiratory rate, and oxygen saturation (SpO2) levels with percentile-based cutoffs can predict the risk of prolonged hospitalization in pediatric asthma exacerbations.
Adding Reslizumab May Benefit Uncontrolled Chronic Rhinosinusitis With Nasal Polyps
Adding reslizumab to mometasone furoate enhanced clinical benefits of the intranasal corticosteroid alone in patients with uncontrolled chronic rhinosinusitis with nasal polyps and peripheral eosinophilia.
Adding Umeclidinium to ICS/LABA Improves Lung Function, Exacerbation Rate in Asthma
Patients with asthma that is poorly controlled by ICS/LABA therapy may experience improvement in lung function with the addition of umeclidinium and/or doubling of the corticosteroid fluticasone furoate.
Dupilumab Demonstrates Long-Term Efficacy, Safety for Improving Asthma Control
Treatment with monoclonal antibody and dual IL-4/IL-13 inhibitor dupilumab was well tolerated and associated with sustained improvement in asthma control for up to 96 weeks
Want to read more?
Please login or register first to view this content.